Job title: Chairman, President & Chief Executive Officer
Dr. Jay M. Short is Chairman, CEO and cofounder of BioAtlaâ and is coinventor of BioAtla’s proprietary Conditionally Active Biologics (CAB) platform. BioAtla is a clinical stage company with headquarters in San Diego and operations in Beijing. He is also Chairman and co-founder of Himalaya Therapeutics, a subsidiary of BioAtla focused on developing immuno-oncology CAB based therapeutics for Asia. He is a cofounder and director of F1 Oncology that is developing CAB-CAR-T therapies for solid tumors. In addition, he is the Chairman and founder of Inversagen, a pioneering company developing therapies targeting chronic diseases associated with aging. He is founder and former Pres. of the E.O. Wilson Biodiversity Foundation and prior to this, was a founder of Diversa Corp. (now BASF), a pioneer in protein discovery and evolution from microbial biodiversity, where he served as CEO, Pres. and CTO and led the company in achieving the largest biotech IPO. Dr. Short also served as Pres. of Stratacyte, an antibody engineering company, and VP R&D and Operations for Stratagene (now Agilent) a leading research supply company. He earned his PhD in Biochemistry at CWRU and his BA in chemistry with honors at Taylor Univ. Dr. Short was the recipient of two first place awards from UCSD- Connect Innovative Product Program, including for the development of the first combinatorial antibody discovery library (while at Stratagene and in collaboration with Scripps Clinic) and for the development of a key FDA approved transgenic genotoxicity testing model (Big Blue). He has authored more than 100 publications and is named inventor of over 300 issued patents and several hundred pending patents. His patents ranked in the top ten based on citation frequency on the 2003 and 2004 Patent Scorecard by MIT Survey across all industries. In addition, He has served on the NRC panel for Chemical Science and Technology at NIST. In 2003 he received the ABL Innovations in HealthCare Gold award, and in 2004 he received the Henry F. Whalen, Jr. Award for Business Development by ACS. In 2006 Dr. Short was shortlisted by the editors of Nature Biotechnology as a personality making the most significant contribution to biotech in the past decade. In 2010 he received an International Best-of-the-Best award from YPO.